Given their effects on glutamatergic signalling, and particularly on NMDA receptor activity, mGlu5 modulators are promising agents for treatment of psychiatric disorders, particularly the currently untreatable cognitive symptoms. Here, GRM5 is linked to psychiatric disorder.